Huffman, Mark D.
Baldridge, Abigail S.
Lazar, Danielle
Abbas, Hiba
Mejia, Jairo
Flowers, Fallon M.
Quintana, Adriana
Jackson, Alema
Kandula, Namratha R.
Lloyd-Jones, Donald M.
Persell, Stephen D.
Khan, Sadiya S.
Paparello, James J.
Chopra, Aashima
Tripathi, Priya
Vu, My H.
Chow, Clara K.
Ciolino, Jody D.
Article History
Received: 19 January 2024
Revised: 23 February 2024
Accepted: 1 March 2024
First Online: 8 April 2024
Compliance with ethical standards
:
: MDH has received travel support from the American Heart Association and World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. CKC has a patent for quarter-dose, quadruple drug combination therapy for blood pressure lowering. SDP receives unrelated research support from Omron Healthcare Co. Ltd. and honoraria for speaking from Omron Healthcare Co. and the National Committee for Quality Assurance. The remaining authors have nothing to disclose.